Reply to price et al and to pea and viale

Clinical Infectious Diseases

Volumn 49, Issue 4, 2009, Pages 643-645

  Viladomiu, Alex Soriano ^a   Martínez, José A ^a   Mensa, Josep ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTEREMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG CHOICE; DRUG EFFICACY; HUMAN; KIDNEY FUNCTION; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SHOCK; STAPHYLOCOCCUS AUREUS; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 67651124623     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/603590     Document Type: Letter

References (19)

1. Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009; 48:997-8.
2. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
3. Soriano A, Martinez JA, Mensa J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000; 30:368-73.
4. Pea F, Viale P. Is the minimum inhibitory concentration of vancomycin an infallible predictor of the clinical outcome of Staphylococcus aureus bacteremia treated with vancomycin? Clin Infect Dis 2009; 49:642-3 (in this issue).
5. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006;42: 1764-71.
6. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000; 57(Suppl 2):S4-9 (erratum: Am J Health Syst Pharm 2001; 58:78).
7. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536-42.
8. del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, Dominguez-Gil A, Sanchez NA. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007; 33:279-85.
9. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of meth- icillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-2402.
10. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Che- mother 2008; 52:3315-20.
11. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45:2460-7.
12. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009; 63:1050-7.
13. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (≥4 grams/day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52:1330-6.
14. Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staph-ylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33:1983-7.
15. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-44.
16. Traczewski MM, Katz BD, Steenbergen JN, Brown SD. Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. Antimicrob Agents Chemother 2009;53: 1735-8.
17. Jones RN. Microbiological features of vanco- mycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42(Suppl 1):S13-24.
18. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208-15.
19. Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the E test GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2009; 63:489-92.